BamSEC and AlphaSense Join Forces
Learn More

XOMA Royalty Corporation – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: XOMA    
Share price (6/2/26): $41.69    
Market cap (6/2/26): $523 million
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 3 pages Amendment No. 1 to the Agreement and Plan of Merger
12/34/56
EX-2.1
from 8-K 72 pages Agreement and Plan of Merger by and Among Ligand Pharmaceuticals Incorporated as Parent Flex Merger Sub, Inc. as Merger Sub and XOMA Royalty Corporation as the Company Dated as of April 27, 2026
12/34/56
EX-2.2
from 8-K 34 pages Contingent Value Rights Agreement
12/34/56
EX-2.1
from 8-K 87 pages Dated August 20, 2025 XOMA Royalty Corporation Xra 5 Corp. and Mural Oncology PLC Transaction Agreement
12/34/56
EX-2.2
from 8-K 33 pages Contingent Value Rights Agreement
12/34/56
EX-2.1
from 8-K 134 pages Agreement and Plan of Merger Dated as of August 4, 2025 Among XOMA Royalty Corporation Xra 4 Corp. and Hillevax, Inc
12/34/56
EX-2.2
from 8-K 25 pages Contingent Value Rights Agreement
12/34/56
EX-2.1
from 8-K 105 pages Agreement and Plan of Merger Among XOMA Royalty Corporation Xra 3 Corp. and Turnstone Biologics Corp. Dated as of June 26, 2025
12/34/56
EX-2.1
from 8-K 75 pages Nevada Plan of Conversion
12/34/56
EX-2.2
from 8-K 30 pages This Contingent Value Rights Agreement, Dated as of April 3, 2024 (This “Agreement”), Is Entered Into by and Between XOMA Corporation, a Delaware Corporation (The “Parent”), Xra 1 Corp., a Delaware Corporation and a Wholly Owned Subsidiary of Parent (The “Purchaser”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania Limited Liability Company, as Rights Agent (As Defined Herein), and Fortis Advisors LLC, a Delaware Limited Liability Company, Solely in Its Capacity as the Initial Representative, Agent and Attorney In-Fact of the Holders (The “Representative”)
12/34/56
EX-2.1
from 8-K 102 pages Agreement and Plan of Merger Dated as of February 16, 2024 Among XOMA Corporation Xra 1 Corp. and Kinnate Biopharma Inc
12/34/56
EX-2
from 8-K 2 pages FDA Advises Public of Serious Adverse Event With Psoriasis Drug Raptiva
12/34/56
EX-2
from 8-K 18 pages Non-Exclusive License Agreement
12/34/56
EX-2
from 8-K 90 pages XOMA Ltd. 6.50% Convertible Snapssm Due 2012 Indenture Dated as of February 10, 2006 Wells Fargo Bank, National Association Trustee
12/34/56
EX-2
from 8-K/A ~50 pages License Agreement
12/34/56
EX-2
from 8-K/A >50 pages Collaboration Agreement
12/34/56
EX-2
from 8-K/A ~50 pages Co-Dev. & Co-Comm. Agreement
12/34/56
EX-2
from 8-K/A ~50 pages License Agreement
12/34/56
EX-2
from 8-K/A ~50 pages License Agreement
12/34/56
EX-2
from 8-K/A ~50 pages Plan of reorganization, merger, acquisition or similar
12/34/56